Drug Profile


Alternative Names: U 62066E

Latest Information Update: 01 Jul 1997

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Antiarrhythmics; Opioid analgesics
  • Mechanism of Action Opioid kappa receptor agonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Pain; Parkinson's disease

Most Recent Events

  • 01 Jul 1997 A clinical study has been added to the pharmacodynamics section
  • 03 Aug 1995 Discontinued-II for Pain in USA (Unknown route)
  • 03 Aug 1995 Discontinued-II for Pain in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top